Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
Author:
Affiliation:
1. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield CT USA
2. Boehringer Ingelheim GmbH & Co. KG; Ingelheim Germany
3. CRS Clinical Research Services; Kiel Germany
4. Boehringer Ingelheim Pharma GmbH & Co KG; Biberach Germany
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12182/fullpdf
Reference14 articles.
1. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030;Whiting;Diabetes Res Clin Pract,2011
2. WHO http://www.who.int/features/factfiles/diabetes/facts/en/index4.html
3. Evolving treatment strategies for the management of type 2 diabetes;Cefalu;Am J Med Sci,2012
4. Overview of newer agents: where treatment is going;DeFronzo;Am J Med,2010
5. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012
Cited by 102 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?;Current Hypertension Reports;2024-06-24
2. Development and Validation of Fast and Sensitive RP-HPLC Stability Indicating Method for Quantification of Teneligliptin in Bulk Drug;J CHROMATOGR SCI;2024
3. Empagliflozin in the treatment of heart failure;Future Cardiology;2024-04-25
4. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter‐2 inhibitor, in type 2 diabetes;Diabetes, Obesity and Metabolism;2024-04-15
5. Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption;The Journal of Clinical Pharmacology;2024-02-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3